30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

ConMed Reports 3Q17 Arthroscopy/Soft Tissue Repair Revenue -

ConMed posted 3Q17 arthroscopy/soft tissue repair revenue of US $98.6MM, -0.8% vs. 3Q16, and YTD revenue of $307.9MM, -0.8% vs. the prior year.

  3Q17 3Q16 $ Change % Change
Arthroscopy/Soft Tissue Repair $98.6 $99.4 -$0.8 -0.8%


  9Mo17 9Mo16 $ Change % Change
Arthroscopy/Soft Tissue Repair $307.9 $310.6 -$2.6 -0.8%

ConMed’s -0.8% year-over-year revenue decrease for the 9 months ended September 2017 is an improvement from its position at this time last year, when 9 months ended September 2016 posted a decrease of -4.4%.

The revenue decrease for 3Q17 and year-to-date are attributed to increased sales of sports medicine single-use products that were offset by declines in capital equipment sales.

Ex-U.S. sales achieved a sixth consecutive quarter of growth at +5.0%, benefitting from strong sports medicine performance, though U.S. orthopaedic revenue continues to struggle, dropping by -8.8%. Domestic revenues were reduced by ~$1.2MM due to weather-related deferred or lost sales in Florida, South Carolina and Texas.

Still, the contribution from new products, new purchasing contracts and salesforce development is expected to bolster U.S. revenue through the close of the year. ConMed is on track to release three more products by year-end, bringing its full-year total to 20 new products. Further, the early-3Q17 acquisition of MedShape’s ExoShape Anterior Cruciate Ligament fixation system should contribute to upward momentum.

Source: ConMed Corporation

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.